REPORT OUTLOOK
Market Size | CAGR | Dominating Region |
---|---|---|
USD 34.9 Billion By 2032 | 8.60% | North America |
By Type | By Application | By End-User |
---|---|---|
|
|
|
SCOPE OF THE REPORT
AI-Based Digital Pathology Solutions Market
Global AI-Based Digital Pathology Solutions Market Size Was Estimated At USD 24.1 Billion In 2023 And Is Projected To Reach USD 34.9 Billion By 2032, At CAGR Of 8.60% (2024-2032)
The AI ​​digital pathology solutions market is revolutionizing the field of pathology by leveraging AI to improve diagnostic accuracy and efficiency. As healthcare systems around the world strive for better patient outcomes and simplified workflows, the integration of AI into digital pathology offers transformative potential. These state-of-the-art solutions enable pathologists to analyze vast amounts of data with unprecedented speed and accuracy, facilitating early disease detection and personalized treatment plans. This blog examines the current landscape of the AI-based digital pathology market, exploring key trends, technological advances and the profound impact on healthcare.
Artificial intelligence (AI) has proven to be a faster and more efficient way to detect and evaluate pathological characteristics of samples than previous technologies. The introduction of artificial intelligence will improve and improve the drug discovery process, and the diagnostic process can be accelerated and strengthened. In addition, AI helps pathologists make accurate diagnoses using data to verify findings. This can alert them if their conclusions contradict the algorithms’ expectations. As a result, AI-based pathology solutions may become increasingly popular.
By combining artificial intelligence (AI) with digital pathology, pathologists can now perform image analysis on more slides in less time by combining AI and digital pathology as a validation tool. Pathologists can improve outcomes by focusing on specific areas and improving efficiency accordingly. Digital pathology increases patient engagement with AI as devices and applications provide access to electronic health information, radiology images, etc.
The use of artificial intelligence in healthcare is becoming increasingly common, especially in relation to pathological diagnosis to improve patient care. For example, a clinical decision system is an AI-based tool designed to streamline workflow processes and improve care for hospital patients. Roche Group announced in October 2021 that it has signed an agreement with Pathani, a technology leader in artificial intelligence-based pathology. The agreement describes the development and distribution of the embedded image analysis workflow to pathologists in accordance with this development and distribution agreement. The result of this partnership is the development of an AI-based medical device that includes a scanner, analysis, control system and algorithm.
AI-Based Digital Pathology Market Report Scope
ATTRIBUTE | DETAILS |
Market Size Value In 2023 | USD 24.1 Billion |
Revenue Forecast In 2032 | USD 34.9 Billion |
Growth Rate CAGR | CAGR of 8.60% from 2024 to 2032 |
Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2023 to 2032 |
Forecast Year | 2024-2032 |
Historic Year | 2019 to 2023 |
By Type |
|
By End-User |
|
By Region |
|
Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Competitive Landscape | PathAI,, Paige.AI,, Akoya Biosciences,, Aiforia,, aetherAI,, CellCarta,, Deep Bio Inc.,, DoMore Diagnostics,, PROSCIA,, Pramana, Inc.,, Visiopharm A/S,, Roche Tissue Diagnostics,, Indica Labs,, Ibex Medical Analytics,, LDPath,, OracleBio Limited,, Verily,, Mindpeak GmbH,, Proscia Inc.,, SamanTree Medical SA,, Tempus AI,, Techcyte, Inc.,, Tribun Health |
Market Dynamics
Market Drivers
Rising incidence of cancer and chronic diseases: The increasing prevalence of cancer and other chronic diseases increases the demand for effective diagnostic solutions. Digital pathology powered by AI provides accurate and rapid analysis to aid in early detection and treatment planning.
Advances in Artificial Intelligence and Machine Learning: The continuous development of artificial intelligence and machine learning algorithms has greatly improved the accuracy and efficiency of digital pathology solutions. Advanced image analysis and pattern recognition capabilities transform diagnostic workflows.
The need for efficient and accurate diagnosis: traditional pathological methods are often time-consuming and prone to human error. AI-powered digital pathology delivers more accurate and consistent results, reducing diagnostic errors and improving patient outcomes.
Shortage of pathologists: there is a global shortage of qualified pathologists, increasing workloads and delaying diagnosis. AI-based solutions help ease this burden by automating routine tasks and providing decision-making support to the pathologist.
The spread of telepathology: The integration of artificial intelligence into digital pathology facilitates remote consultations and second opinions, making it easier for pathologists to collaborate and share knowledge across locations. This is especially useful in underserved areas.
Market Restraining Factors:
High initial costs: Developing AI-based digital pathology solutions requires significant investment in advanced hardware, software and infrastructure. High upfront costs can be a barrier for smaller healthcare facilities and laboratories.
Data Protection and Security Issues: The processing of sensitive patient data presents significant data protection and security issues. Ensuring compliance with strict regulations such as HIPAA in the US and GDPR can be difficult and costly, which hinders market growth.
Limited Awareness and Adoption: Despite the benefits of AI-based digital pathology, awareness and acceptance among pathologists and healthcare providers remains limited. Resistance to change and reliance on traditional methods can hinder market access.
Technical challenges: Integrating AI solutions into existing laboratory information systems and workflows can be technically challenging. Interoperability issues, data integration and the need for extensive training can slow down the implementation process.
Regulatory Barriers: The regulatory approval process for AI-based medical devices can be long and rigorous. Meeting clinical validation standards and obtaining necessary regulatory approvals may delay market entry and expansion.
Market Trends
- Increased Adoption of AI in Pathology
- Rising Demand for Remote Diagnostics
- Integration with Cloud Computing
- Advancements in Machine Learning Algorithms
- Growing Investment in Healthcare AI
- Collaboration Between Tech Companies and Healthcare Providers
- Regulatory Approvals and Standardizations
- Enhanced Image Analysis and Data Management
- Personalized Medicine and Targeted Therapies
- Expansion of Telepathology Services
- Development of Robust AI Training Datasets
- Focus on Reducing Diagnostic Errors and Improving Accuracy
Key Players
- PathAI,
- AI,
- Akoya Biosciences,
- Aiforia,
- aetherAI,
- CellCarta,
- Deep Bio Inc.,
- DoMore Diagnostics,
- PROSCIA,
- Pramana, Inc.,
- Visiopharm A/S,
- Roche Tissue Diagnostics,
- Indica Labs,
- Ibex Medical Analytics,
- LDPath,
- OracleBio Limited,
- Verily,
- Mindpeak GmbH,
- Proscia Inc.,
- SamanTree Medical SA,
- Tempus AI,
- Techcyte, Inc.,
- Tribun Health
Recent Development:
-
In January 2024, Roche announced that it had entered into a final merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately held US company in Berkeley, California. A variety of preclinical programs and clinically stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes are part of Carmot’s research and development portfolio.
-
In November 2023, Leica Biosystems further strengthened its partnership with hospitals and laboratories worldwide later to make use of the innovative digital pathology workflows. Building on their prior partnership, Leica Biosystems has selected Paige to supply their Aperio GT 450 digital pathology slide scanners with view and manage digital pathology images software and a range of embedded AI technologies.
Regional Analysis
North America
Market Leadership: North America holds the largest share in the AI-based digital pathology market, primarily driven by advanced healthcare infrastructure and significant adoption of AI technologies.
Key Growth Drivers: Strong presence of major market players, rising prevalence of cancer, and increasing adoption of digital pathology for diagnostic purposes.
Europe
Technological Advancements: Europe is another major market, driven by growing investments in AI research and high healthcare expenditure.
Adoption Rate: Countries like the UK, Germany, and France are leading in the adoption of AI-based pathology solutions due to increasing cancer cases and government support.
Collaborative Efforts: Growing collaboration between technology firms and healthcare providers in the region supports innovation and widespread adoption.
Market Opportunities
- Enhanced Diagnostic Accuracy
- Reduction in Diagnostic Turnaround Time
- Integration with Electronic Health Records (EHR)
- Growing Adoption of Telepathology
- Personalized Medicine Advancements
- Support for Pathologist Workloads
- Expansion in Emerging Markets
- Collaborations and Partnerships in Healthcare
- Development of Cost-Effective AI Solutions
- Regulatory Approvals and Standardizations
Market Insights
Technological Advances: The integration of artificial intelligence into digital pathology is revolutionizing the field by enabling automatic image analysis, reducing diagnostic errors and increasing efficiency. AI algorithms can detect patterns and anomalies that the human eye might miss, leading to more accurate and timely diagnoses.
Increasing Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases, especially cancer, is a major factor in the adoption of AI-based digital pathology solutions. These techniques provide strong support for tumor detection and classification, which helps develop individualized treatment plans.
Increasing adoption in clinical settings: Hospitals and diagnostic laboratories are increasingly adopting AI-based digital pathology systems to improve workflow efficiency and diagnostic accuracy. The transition to digital pathology is also driven by the need for remote consultations and telepathology, especially after the COVID-19 pandemic.
Cost-effectiveness and scalability: AI-based solutions can process large volumes of data quickly and cost-effectively. This scalability is critical for large healthcare and research institutions to manage and analyze large pathology data.
Regulatory Approvals and Collaborations: The market is seeing an increase in the number of regulatory approvals and strategic collaborations between technology companies and healthcare providers. These partnerships are essential to the development and widespread adoption of innovative AI-based pathology solutions.
Market Segmentation
By Type Of Target Disease Indication
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Gastrointestinal Cancer
- Lung Cancer
- Prostate Cancer
- Other Indications
By Application
- Diagnostics
- Research
- Other Applications
By End-User
- Academic Institutions
- Hospitals/Healthcare Institutions
- Laboratories/Diagnostic Institutions
- Research Institutes
- Other End Users
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America
- S.
- Canada
Europe
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
FAQ
AI-Based Digital Pathology Solutions Market Size Was Estimated At USD 24.1 Billion In 2023 And Is Projected To Reach USD 34.9 Billion By 2032.
The Global AI-Based Digital Pathology Solutions Market is predicted to grow at an 8.60% CAGR during the forecast period for 2024-2032.
PathAI,, Paige.AI,, Akoya Biosciences,, Aiforia,, aetherAI,, CellCarta,, Deep Bio Inc.,, DoMore Diagnostics,, PROSCIA,, Pramana, Inc.,, Visiopharm A/S,, Roche Tissue Diagnostics,, Indica Labs,, Ibex Medical Analytics,, LDPath,, OracleBio Limited,, Verily,, Mindpeak GmbH,, Proscia Inc.,, SamanTree Medical SA,, Tempus AI,, Techcyte, Inc.,, Tribun Health.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.